Linklaters advised the EIC Fund (European Innovation Council Fund) on the deal.Created in 2014, XENOTHERA is a French biotech developing a technological platform of glyco-humanized polyclonal…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
